BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WhitePaper

Reading the Register: What Japan's Provision Plans Actually Say

A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...

August 10, 2026 | Analysis

Aging Is Not an Indication. Asia-Pacific Found Three Ways Around It.

Feature | Longevity and geroscience | BioPharma APAC The closed front door Start with the fact that shapes everything else. There is no jurisdiction on...

August 07, 2026 | Analysis

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 04, 2026 | Analysis

7 Manufacturing Technologies Moving From Pilot to Plant in APAC

HOW THE SEVEN WERE CHOSEN Inclusion required evidence of at least two commercial-scale installations in the region, with sites named wherever publ...

August 03, 2026 | Analysis

12 Funding Rounds That Show Where APAC Biotech Capital Is Going

There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...

July 30, 2026 | News

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

APAC Physicians Back Pulsed Field Ablation, But Referral Gaps Delay AFib Treatment

Growing physician confidence in pulsed field ablation highlights the need to strengthen referral pathways, education and healthcare system readiness - Bos...

July 29, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

Discount or Validation? Western Pharma’s Appetite for Chinese Assets

There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...

July 24, 2026 | Analysis

The Bioreactors Are Ours. The Consumables Are Not.

A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...

July 22, 2026 | Analysis

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

July 15, 2026 | Regulatory

Stay Connected